Navigation Links
DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
Date:2/8/2011

WASHINGTON, Feb. 8, 2011 /PRNewswire/ -- DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients. The study will eventually be introduced to other military hospitals and results will be collected on multiple cancers. Previous studies published by DiaTech have demonstrated the MiCK assay can increase the patient's response to chemotherapy, resulting in increased patient survival. In addition, the assay can guide the physician on single vs. combination therapy and when generic vs. proprietary drugs are more effective.  

"To be able to predict the best chemotherapy treatment for cancer patients has been a goal for oncologists for many years and we now have the data that proves this technology works for all cancers. In addition the test can guide a physician on choosing between single drug or combination treatments and whether to use less expensive generic drugs or newer proprietary drugs based on which drugs will give the patient the most effective response," said Dr. Cary Presant, DiaTech Medical Director, and Professor of Clinical Medicine at the University of Southern California Keck School of Medicine.In the MiCK assay, the tumor cells of an individual patient are exposed to multiple doses of several chemotherapeutic drugs either as single drugs or in combinations. A sophisticated algorithm is used to monitor and compute the amounts of apoptosis caused by each of the drugs to establish a drug sensitivity profile of the patient's tumor cells. Knowledge of a patient's drug sensitivity profile allows the treating oncologists to prescribe chemotherapy that would be the most effective against the tumor cells of that patient.

No other technology in the market today can measure apoptotic cancer cell death directly and predict chemotherapy treatment. The capabilities and performance of the MiCK assay technology far exceed those of any other cancer testing assays available in the current market. It is the only test assay available today with proof-of-concept outcome data, utilizing 45 different chemotherapy agents and numerous combinations of drug therapy. The MiCK assay has been used successfully to test all types of cancers.

DiaTech Oncology is a privately held clinical pathology laboratory working to help oncologists and their patients deal with the devastating effects of cancer. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay. The MiCK assay is the only test available that measures the chemotherapeutic drug effect for a specific patient kinetically and accurately.Contact:Steve Latimer1-866-556-5356http://www.diatech-oncology.com info@diatechoncology.com This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE DiaTech Oncology
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2. TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch
3. Sentinel Oncology add ADME From O2h to Their New Extended Contract
4. US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials
5. US Oncology to Report 2010 Third Quarter Operating Results
6. Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
7. Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
10. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
11. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017 Synthetic Biologics, Inc. (NYSE ... the microbiome to protect and restore the health of patients, intends ... December 31, 2016 on Thursday, March 2, 2017, and to host ... dial-in information for the call is as follows: U.S. ... ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... to announce that Dr. Trevor Heritage has joined its executive team to lead ... system designed to provide insights to help improve the diagnosis and treatment of ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 ... announced that apatorsen results from two randomized Phase 2 clinical ... (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 th - ... data from trials in bladder and prostate cancers demonstrated apatorsen ... with standard-of-care treatments. ...
(Date:2/21/2017)... Feb 21, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 12.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):